Siemens develops RAPID2 system for fast discovery of pathogen
16 June 2009
Siemens Corporate Research (SCR), Inc. has developed the RAPID2
system to speed the biomarker discovery process for the development of
rapid diagnostic tests. This system marries the power of information
technology with today's improved genomic sequencing to quickly identify
genomic signatures unique to the set of organisms to be detected.
These signatures are the foundation for a new generation of molecular
diagnostic tests for the rapid detection of healthcare-associated
infections such as the potentially deadly Methicillin-Resistant
Staphylococcus Aureus (MRSA).
Gayle Wittenberg, Program Manager at Siemens Corporate Research's
Princeton, New Jersey-based research and development center, along with
her Princeton and Erlangen, Germany colleagues, have been utilizing
complex information technology models to focus on genetic targets that
quickly identify pathogenic bacteria.
"The advantage of our RAPID2 system is that it provides an efficient
framework for quickly identifying new biomarkers based on the genomic
sequence of a particular pathogen," says Dr. Wittenberg. "In the event
of a pandemic, such as the recent H1N1 Flu outbreak, our system would
enable a rapid response with the development of a strain-specific
diagnostic test. This would help medical professionals manage an
outbreak more effectively from the outset."
SCR used its new system recently to quickly discover a DNA barcode
for detecting the H1N1 Flu after they received the genomic sequences of
the virus isolated from infected patients from the National Institute of
In addition to applications related to healthcare-associated
infections and disease outbreaks, SCR's RAPID2 system is suited for use
within the food and water industries where products are tested for
microbial contamination, as well for discovering genetic targets for
Bookmark this page